Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 100

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 100
---
 a 1:1 ratio; (ii) the issuance of 609,888 Ordinary Shares upon the automatic conversion of the $900,000 outstanding principal          
 of the 2020 CLAs, which will occur upon the completion of this offering; (iii) the issuance of 553,640 Ordinary Shares upon the automatic 
 conversion of the $450,000 outstanding principal of 2024 CLAs, which will occur upon the completion of this offering; (iv) the receipt    
 of an additional $100,000 under the Bridge Loan subsequent to December 31, 2024; (v) the receipt of a loan in the total amount of         
 $200,000 pursuant to the 2025 Loan Agreements; and (vi) the expiration of certain outstanding warrants to purchase up to 167,365          
 Ordinary Shares in March 2025.                                                                                                            |

| ● | on a pro forma as adjusted basis to give further effect to: (i)                                                                          
 the sale of 1,000,000 Ordinary Shares in this offering at an initial public offering price of $11.00 per Ordinary Share,                 
 which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and      
 commissions and estimated offering expenses payable by us; (ii) repayment of the Bridge Loan in the total amount of $350,000 plus        
 accrued interest and an aggregate risk premium in the amount of $105,000; (iii) the repayment of the loan under the 2024 Loan Agreements 
 in the total amount of $150,000 plus accrued interest and an aggregate risk premium in the amount of $50,000; (iv) the repayment         
 of the loan under the December 2024 Loan Agreement in the total amount of $117,000 plus accrued interest and an aggregate risk premium   
 of approximately $35,100; and (v) the repayment of the loan under the 2025 Loan Agreements in the total amount of $200,000 plus accrued  
 interest and an aggregate risk premium in the amount of $100,000;                                                                        |

The pro forma as adjusted
information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other
terms of this offering determined at pricing.

You should read this table
in conjunction with the sections titled “Use of Proceeds”, “Selected Financial Data”, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and